RE:RE:RE:RE:RE:RE:G12D/G12V KRAS mutation in PC & CRC patients respond to PelaIn 2021 Titto Augustine, Sanjay Goel, et al. found for the first time that immune-insensitive MSS tumors that account for 85% of all CRC can be effectively converted to immunotherapy-sensitive cancers by introducing reovirus to the therapeutic regimen. They reported that their data confidently establishes that reovirus sensitizes MSS tumors to anti-PD-1 therapy via increasing the expression of PD-L1 marker on respective target cells.
Combinatorial treatment activated the innate immune system, pattern recognition receptors, and antigen presentation markers. Furthermore, the investigators observed the reduction of immunosuppressive macrophages and expansion of effector T cell subsets, as well as reduction in T cell exhaustion. The current investigation sheds light on the immunological mechanisms of the reovirus-anti-PD-1 combination to reduce the growth of MSS CRC.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9642964/
In this multi-center, biomarker driven, phase I study, the combination of FOLFIRI/bevacizumab chemotherapy with pelareorep was well tolerated; the highest doses of each individual drug was easily deliverable; strong efficacy signals were observed at the RPTD; and correlative science demonstrated a unique immune enhancing phenomenon, and electron microscopic characteristics.